Abdi Ibrahim

Focus: Abdi Ibrahim is a Turkish biotechnology company focused on small molecule therapeutics in neurology and metabolic diseases. The company maintains an active pipeline spanning Phase 1 through Phase 4 programs.

Neurology Metabolic Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Abdi Ibrahim

AI assessmentNot Hiring

No open roles listed right now. Follow Abdi Ibrahim to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Metabolic Syndrome

N/A

Clinical Trials (1)

NCT02379702Metabolic Syndrome Prevalence Study

N/A

Help build intelligence for Abdi Ibrahim

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline diversity across therapeutic areas with 11 active trials provides exposure to multiple disease states and regulatory pathways
Phase 3 and Phase 4 programs (udenafil, AI201901, aripiprazole) offer near-term regulatory catalysts and commercialization opportunities
Small molecule focus enables development of oral, accessible therapies with broad market potential in high-burden indications

Watch Out For

Zero active job postings suggest minimal hiring activity or potential organizational constraints
Limited public financial, revenue, and R&D intensity data restricts visibility into company stability and growth trajectory

Generated by Claude from Abdi Ibrahim's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Ferritin, iron and iron binding capacity, high sensitive C-reactive protein

Iron-deficiency

N/A

Clinical Trials (1)

NCT03957187Prevalence and Clinical Associates of Iron Deficiency in Patients With Atrial Fibrillation

N/A

dirithromycin

Bioequivalence

Phase 1

Clinical Trials (4)

NCT02237768Semi-replicate Crossover Bioequivalence Study of Dirithromycin of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions

Phase 1

NCT02185846Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fed Condition

Phase 1

NCT02185833Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fasting Condition

Phase 1

+1 more

EPs® 7630

Hand, Foot, and Mouth Disease

Phase 2/3

Clinical Trials (1)

NCT06353477Hand, Foot, and Mouth Disease: Could EPs®7630 be a Treatment Option

Phase 2/3